Our recent prospective phase II single-arm study has revealed that combination regimen of G-CSF and rhTPO is safer and improves the curative effect on elderly patients with acute myeloid leukemia (AML) [19]. This evidence concerns the gene CSF3 and acute myeloid leukemia.